Ingevity Corp (NGVT) FY2025 10-K Annual Report

Filed: Feb 26, 2026
Health Care
Chemicals & Allied ProductsSEC EDGAR

Ingevity Corp (NGVT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.

Ingevity Corp FY2025 10-K Analysis

Business Overview

  • Core business: Specialty chemicals and materials manufacturing, focusing on automotive carbon, pavement, and road marking technologies
  • Legal expense accrual of $95.4M for patent infringement judgment against BASF, final appeal lost in Feb 2026, impacting financials and cash flow
+3 more insights

Risk Factors

  • Regulatory risk: EU GDPR, CCPA, and China Cybersecurity Law impose complex data privacy compliance and significant fines for violations
  • Geopolitical risk: 43% sales outside US exposed to tariffs and retaliatory measures by China harming Performance Materials and Chemicals margins
+3 more insights

Ingevity Corp FY2025 Key Financial Metrics
XBRL

Revenue

$1.2B

-17.0% YoY

Net Income

-$167M

+61.2% YoY

Gross Margin

39.5%

+719bp YoY

Operating Margin

35.9%

+962bp YoY

Net Margin

-14.3%

+1628bp YoY

ROE

-562.6%

-34219bp YoY

Total Assets

$1.7B

-18.4% YoY

EPS (Diluted)

$-4.61

+61.1% YoY

Operating Cash Flow

$331M

+157.5% YoY

Source: XBRL data from Ingevity Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Ingevity Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.